Cancer‑associated fibroblasts in human malignancies, with a particular emphasis on sarcomas (Review)

Riley RS, June CH, Langer R and Mitchell MJ: Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 18:175–196. 2019. View Article : Google Scholar : PubMed/NCBI

Mondal M, Guo J, He P and Zhou D: Recent advances of oncolytic virus in cancer therapy. Hum Vaccin Immunother. 16:2389–2402. 2020. View Article : Google Scholar : PubMed/NCBI

Soerjomataram I and Bray F: Planning for tomorrow: Global cancer incidence and the role of prevention 2020-2070. Nat Rev Clin Oncol. 18:663–672. 2021. View Article : Google Scholar : PubMed/NCBI

Chen X and Song E: Turning foes to friends: Targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 18:99–115. 2019. View Article : Google Scholar

D'Agostino S, Tombolan L, Saggioro M, Frasson C, Rampazzo E, Pellegrini S, Favaretto F, Biz C, Ruggieri P, Gamba P, et al: Rhabdomyosarcoma cells produce their own extracellular matrix with minimal involvement of Cancer-associated fibroblasts: A preliminary study. Front Oncol. 10:6009802020. View Article : Google Scholar

Sarkar M, Nguyen T, Gundre E, Ogunlusi O, El-Sobky M, Giri B and Sarkar TR: Cancer-associated fibroblasts: The chief architect in the tumor microenvironment. Front Cell Dev Biol. 11:10890682023. View Article : Google Scholar : PubMed/NCBI

Pillozzi S, Bernini A, Palchetti I, Crociani O, Antonuzzo L, Campanacci D and Scoccianti G: Soft tissue sarcoma: An insight on biomarkers at molecular, metabolic and cellular level. Cancers. 13:30442021. View Article : Google Scholar : PubMed/NCBI

Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, Fearon D, Greten FR, Hingorani SR, Hunter T, et al: A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 20:174–186. 2020. View Article : Google Scholar : PubMed/NCBI

Maia A, Schollhorn A, Schuhmacher J and Gouttefangeas C: CAF-immune cell crosstalk and its impact in immunotherapy. Semin Immunopathol. 45:203–214. 2023. View Article : Google Scholar :

Kennel KB, Bozlar M, De Valk AF and Greten FR: Cancer-associated fibroblasts in inflammation and antitumor immunity. Clin Cancer Res. 29:1009–1016. 2023. View Article : Google Scholar :

Huang H, Wang Z, Zhang Y, Pradhan RN, Ganguly D, Chandra R, Murimwa G, Wright S, Gu X, Maddipati R, et al: Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer. Cancer Cell. 40:656–673.e7. 2022. View Article : Google Scholar :

Kakarla S, Chow KK, Mata M, Shaffer DR, Song XT, Wu MF, Liu H, Wang LL, Rowley DR, Pfizenmaier K and Gottschalk S: Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol Ther. 21:1611–1620. 2013. View Article : Google Scholar : PubMed/NCBI

Chen B, Chan WN, Xie F, Mui CW, Liu X, Cheung AHK, Lung RWM, Chow C, Zhang Z, Fang C, et al: The molecular classification of cancer-associated fibroblasts on a pan-cancer single-cell transcriptional atlas. Clin Transl Med. 13:e15162023. View Article : Google Scholar : PubMed/NCBI

Ohlund D, Elyada E and Tuveson D: Fibroblast heterogeneity in the cancer wound. J Exp Med. 211:1503–1523. 2014. View Article : Google Scholar : PubMed/NCBI

Tsoumakidou M: The advent of immune stimulating CAFs in cancer. Nat Rev Cancer. 23:258–269. 2023. View Article : Google Scholar : PubMed/NCBI

Choi KJ, Nam JK, Kim JH, Choi SH and Lee YJ: Endothelial-to-mesenchymal transition in anticancer therapy and normal tissue damage. Exp Mol Med. 52:781–792. 2020. View Article : Google Scholar : PubMed/NCBI

Lamouille S, Xu J and Derynck R: Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI

Taguchi A, Kawana K, Tomio K, Yamashita A, Isobe Y, Nagasaka K, Koga K, Inoue T, Nishida H, Kojima S, et al: Matrix metalloproteinase (MMP)-9 in cancer-associated fibroblasts (CAFs) is suppressed by omega-3 polyunsaturated fatty acids in vitro and in vivo. PLoS One. 9:e896052014. View Article : Google Scholar : PubMed/NCBI

Cavazzoni A and Digiacomo G: Role of cytokines and other soluble factors in tumor development: Rationale for new therapeutic strategies. Cells. 12:25322023. View Article : Google Scholar : PubMed/NCBI

O'Connell JT, Sugimoto H, Cooke VG, MacDonald BA, Mehta AI, LeBleu VS, Dewar R, Rocha RM, Brentani RR, Resnick MB, et al: VEGF-A and Tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization. Proc Natl Acad Sci USA. 108:16002–16007. 2011. View Article : Google Scholar : PubMed/NCBI

Liu T, Han C, Wang S, Fang P, Ma Z, Xu L and Yin R: Cancer-associated fibroblasts: An emerging target of Anti-cancer immunotherapy. J Hematol Oncol. 12:862019. View Article : Google Scholar : PubMed/NCBI

Robertson-Tessi M, Gillies RJ, Gatenby RA and Anderson AR: Impact of metabolic heterogeneity on tumor growth, invasion, and treatment outcomes. Cancer Res. 75:1567–1579. 2015. View Article : Google Scholar : PubMed/NCBI

Wu D, Zhuo L and Wang X: Metabolic reprogramming of carcinoma-associated fibroblasts and its impact on metabolic heterogeneity of tumors. Semin Cell Dev Biol. 64:125–131. 2017. View Article : Google Scholar

Martinez-Outschoorn UE, Lisanti MP and Sotgia F: Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth. Semin Cancer Biol. 25:47–60. 2014. View Article : Google Scholar : PubMed/NCBI

Tavares-Valente D, Baltazar F, Moreira R and Queiros O: Cancer cell bioenergetics and pH regulation influence breast cancer cell resistance to paclitaxel and doxorubicin. J Bioenerg Biomembr. 45:467–475. 2013. View Article : Google Scholar : PubMed/NCBI

Guo Z, Zhang H, Fu Y, Kuang J, Zhao B, Zhang L, Lin J, Lin S, Wu D and Xie G: Cancer-associated fibroblasts induce growth and radioresistance of breast cancer cells through paracrine IL-6. Cell Death Discov. 9:62023. View Article : Google Scholar : PubMed/NCBI

Yoshida GJ: Regulation of heterogeneous cancer-associated fibroblasts: The molecular pathology of activated signaling pathways. J Exp Clin Cancer Res. 39:1122020. View Article : Google Scholar : PubMed/NCBI

Biffi G, Oni TE, Spielman B, Hao Y, Elyada E, Park Y, Preall J and Tuveson D: IL1-Induced JAK/STAT signaling is antagonized by TGFβ to Shape CAF heterogeneity in pancreatic ductal adenocarcinomacinoma. Cancer Discov. 9:282–301. 2019. View Article : Google Scholar

Rimal R, Desai P, Daware R, Hosseinnejad A, Prakash J, Lammers T and Singh S: Cancer-associated fibroblasts: Origin, function, imaging, and therapeutic targeting. Adv Drug Deliv Rev. 189:1145042022. View Article : Google Scholar : PubMed/NCBI

Strizova Z, Bartunkova J and Smrz D: The challenges of adoptive cell transfer in the treatment of human renal cell carcinoma. Cancer Immunol Immunother. 68:1831–1838. 2019. View Article : Google Scholar : PubMed/NCBI

Chen Y, Yang S, Tavormina J, Tampe D, Zeisberg M, Wang H, Mahadevan KK, Wu CJ, Sugimoto H, Chang CC, et al: Oncogenic collagen I homotrimers from cancer cells bind to α3β1 integrin and impact tumor microbiome and immunity to promote pancreatic cancer. Cancer Cell. 40:818–834.e9. 2022. View Article : Google Scholar

Taborska P, Lukac P, Stakheev D, Rajsiglova L, Kalkusova K, Strnadova K, Lacina L, Dvorankova B, Novotny J, Kolar M, et al: Novel PD-L1- and collagen-expressing patient-derived cell line of undifferentiated pleomorphic sarcoma (JBT19) as a model for cancer immunotherapy. Sci Rep. 13:190792023. View Article : Google Scholar : PubMed/NCBI

Sun X, Wu B, Chiang HC, Deng H, Zhang X, Xiong W, Liu J, Rozeboom AM, Harris BT, Blommaert E, et al: Tumour DDR1 promotes collagen fibre alignment to instigate immune exclusion. Nature. 599:673–678. 2021. View Article : Google Scholar : PubMed/NCBI

Meyaard L: The inhibitory collagen receptor LAIR-1 (CD305). J Leukoc Biol. 83:799–803. 2008. View Article : Google Scholar

Horn LA, Chariou PL, Gameiro SR, Qin H, Iida M, Fousek K, Meyer TJ, Cam M, Flies D, Langermann S, et al: Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-β signaling enables PD-L1-mediated tumor eradication. J Clin Invest. 132:e1551482022. View Article : Google Scholar

Cheng Y, Li H, Deng Y, Tai Y, Zeng K, Zhang Y, Liu W, Zhang Q and Yang Y: Cancer-associated fibroblasts induce PDL1+ neutrophils through the IL6-STAT3 pathway that foster immune suppression in hepatocellular carcinoma. Cell Death Dis. 9:4222018. View Article : Google Scholar : PubMed/NCBI

Cao H, Cheng HS, Wang JK, Tan NS and Tay CY: A 3D physio-mimetic interpenetrating network-based platform to decode the pro and anti-tumorigenic properties of cancer-associated fibroblasts. Acta Biomater. 132:448–460. 2021. View Article : Google Scholar : PubMed/NCBI

Ozdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, et al: Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 25:719–734. 2014. View Article : Google Scholar : PubMed/NCBI

Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, Dekleva EN, Saunders T, Becerra CP, Tattersall IW, et al: Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell. 25:735–747. 2014. View Article : Google Scholar : PubMed/NCBI

Alkasalias T, Flaberg E, Kashuba V, Alexeyenko A, Pavlova T, Savchenko A, Szekely L, Klein G and Guven H: Inhibition of tumor cell proliferation and motility by fibroblasts is both contact and soluble factor dependent. Proc Natl Acad Sci USA. 111:17188–17193. 2014. View Article : Google Scholar : PubMed/NCBI

Gorchs L, Ahmed S, Mayer C, Knauf A, Fernández Moro C, Svensson M, Heuchel R, Rangelova E, Bergman P and Kaipe H: The vitamin D analogue calcipotriol promotes an anti-tumorigenic phenotype of human pancreatic CAFs but reduces T cell mediated immunity. Sci Rep. 10:174442020. View Article : Google Scholar : PubMed/NCBI

Mao X, Xu J, Wang W, Liang C, Hua J, Liu J, Zhang B, Meng Q, Yu X and Shi S: Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: New findings and future perspectives. Mol Cancer. 20:1312021. View Article : Google Scholar : PubMed/NCBI

Bartoschek M, Oskolkov N, Bocci M, Lövrot J, Larsson C, Sommarin M, Madsen CD, Lindgren D, Pekar G, Karlsson G, et al: Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing. Nat Commun. 9:51502018. View Article : Google Scholar : PubMed/NCBI

Newman L: Oncologic anthropology: Global variations in breast cancer risk, biology, and outcome. J Surg Oncol. 128:959–966. 2023. View Article : Google Scholar : PubMed/NCBI

Ma J, Chan JJ, Toh CH and Yap YS: Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer. NPJ Breast Cancer. 9:742023. View Article : Google Scholar : PubMed/NCBI

Pandey K, Katuwal NB, Park N, Hur J, Cho YB, Kim SK, Lee SA, Kim I, Lee SR and Moon YW: Combination of abemaciclib following eribulin overcomes Palbociclib-resistant breast cancer by inhibiting the G2/M cell cycle phase. Cancers (Basel). 14:2102022. View Article : Google Scholar : PubMed/NCBI

Piwocka O, Musielak M, Piotrowski I, Kulcenty K, Adamczyk B, Fundowicz M, Suchorska WM and Malicki J: Primary cancer-associated fibroblasts exhibit high heterogeneity among breast cancer subtypes. Rep Pract Oncol Radiother. 28:159–171. 2023. View Article : Google Scholar : PubMed/NCBI

Kieffer Y, Hocine HR, Gentric G, Pelon F, Bernard C, Bourachot B, Lameiras S, Albergante L, Bonneau C, Guyard A, et al: Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer. Cancer Discov. 10:1330–1351. 2020. View Article : Google Scholar : PubMed/NCBI

Yamashita M, Ogawa T, Zhang X, Hanamura N, Kashikura Y, Takamura M, Yoneda M and Shiraishi T: Role of stromal myofibroblasts in invasive breast cancer: Stromal expression of alpha-smooth muscle actin correlates with worse clinical outcome. Breast Cancer. 19:170–176. 2012. View Article : Google Scholar

Pelon F, Bourachot B, Kieffer Y, Magagna I, Mermet-Meillon F, Bonnet I, Costa A, Givel AM, Attieh Y, Barbazan J, et al: Cancer-associated fibroblast heterogeneity in axillary lymph nodes drives metastases in breast cancer through complementary mechanisms. Nat Commun. 11:4042020. View Article : Google Scholar : PubMed/NCBI

Ershaid N, Sharon Y, Doron H, Raz Y, Shani O, Cohen N, Monteran L, Leider-Trejo L, Ben-Shmuel A, Yassin M, et al: NLRP3 inflammasome in fibroblasts links tissue damage with inflammation in breast cancer progression and metastasis. Nat Commun. 10:43752019. View Article : Google Scholar : PubMed/NCBI

Yang SS, Ma S, Dou H, Liu F, Zhang SY, Jiang C, Xiao M and Huang YX: Breast cancer-derived exosomes regulate cell invasion and metastasis in breast cancer via miR-146a to activate cancer associated fibroblasts in tumor microenvironment. Exp Cell Res. 391:1119832020. View Article : Google Scholar : PubMed/NCBI

Ren J, Smid M, Iaria J, Salvatori DCF, van Dam H, Zhu HJ, Martens JWM and Ten Dijke P: Cancer-associated fibroblast-derived Gremlin 1 promotes breast cancer progression. Breast Cancer Res. 21:1092019. View Article : Google Scholar : PubMed/NCBI

Wu HJ, Hao M, Yeo SK and Guan JL: FAK signaling in cancer-associated fibroblasts promotes breast cancer cell migration and metastasis by exosomal miRNAs-mediated intercellular communication. Oncogene. 39:2539–2549. 2020. View Article : Google Scholar : PubMed/NCBI

Chatterjee A, Jana S, Chatterjee S, Wastall LM, Mandal G, Nargis N, Roy H, Hughes TA and Bhattacharyya A: MicroRNA-222 reprogrammed cancer-associated fibroblasts enhance growth and metastasis of breast cancer. Br J Cancer. 121:679–689. 2019. View Article : Google Scholar : PubMed/NCBI

Mizrahi JD, Surana R, Valle JW and Shroff RT: Pancreatic cancer. Lancet. 395:2008–2020. 2020. View Article : Google Scholar : PubMed/NCBI

Sohal DPS, Kennedy EB, Cinar P, Conroy T, Copur MS, Crane CH, Garrido-Laguna I, Lau MW, Johnson T, Krishnamurthi S, et al: Metastatic pancreatic cancer: ASCO guideline update. J Clin Oncol. 38:3217–3230. 2020. View Article : Google Scholar : PubMed/NCBI

Bekkali NLH and Oppong KW: Pancreatic ductal adenocarcinoma epidemiology and risk assessment: Could we prevent? Possibility for an early diagnosis. Endosc Ultrasound. 6(Suppl 3): S58–S61. 2017. View Article : Google Scholar

Hosein AN, Brekken RA and Maitra A: Pancreatic cancer stroma: An update on therapeutic targeting strategies. Nat Rev Gastroenterol Hepatol. 17:487–505. 2020. View Article : Google Scholar : PubMed/NCBI

Manoukian P, Bijlsma M and van Laarhoven H: The cellular origins of Cancer-associated fibroblasts and their opposing contributions to pancreatic cancer growth. Front Cell Dev Biol. 9:7439072021. View Article : Google Scholar : PubMed/NCBI

Geng X, Chen H, Zhao L, Hu J, Yang W, Li G, Cheng C, Zhao Z, Zhang T, Li L and Sun B: Cancer-associated fibroblast (CAF) heterogeneity and targeting therapy of CAFs in pancreatic cancer. Front Cell Dev Biol. 9:6551522021. View Article : Google Scholar : PubMed/NCBI

Ohlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, Corbo V, Oni TE, Hearn SA, Lee EJ, et al: Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 214:579–596. 2017. View Article : Google Scholar : PubMed/NCBI

Kim HW, Lee JC, Paik KH, Kang J, Kim J and Hwang JH: Serum interleukin-6 is associated with pancreatic ductal adenocarcinoma progression pattern. Medicine (Baltimore). 96:e59262017. View Article : Google Scholar : PubMed/NCBI

Goulet CR, Champagne A, Bernard G, Vandal D, Chabaud S, Pouliot F and Bolduc S: Cancer-associated fibroblasts induce epithelial-mesenchymal transition of bladder cancer cells through paracrine IL-6 signalling. BMC Cancer. 19:1372019. View Article : Google Scholar : PubMed/NCBI

Mirzaei S, Saghari S, Bassiri F, Raesi R, Zarrabi A, Hushmandi K, Sethi G and Tergaonkar V: NF-κB as a regulator of cancer metastasis and therapy response: A focus on epithelial-mesenchymal transition. J Cell Physiol. 237:2770–2795. 2022. View Article : Google Scholar : PubMed/NCBI

Rebelo R, Xavier CPR, Giovannetti E and Vasconcelos MH: Fibroblasts in pancreatic cancer: Molecular and clinical perspectives. Trends Mol Med. 29:439–453. 2023. View Article : Google Scholar : PubMed/NCBI

Richards KE, Zeleniak AE, Fishel ML, Wu J, Littlepage LE and Hill R: Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells. Oncogene. 36:1770–1778. 2017. View Article : Google Scholar :

Aronsson L, Bengtsson A, Toren W, Andersson R and Ansari D: Intraductal papillary mucinous carcinoma versus pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. Int J Surg. 71:91–99. 2019. View Article : Google Scholar : PubMed/NCBI

Aronsson L, Andersson R and Ansari D: Intraductal papillary mucinous neoplasm of the pancreas-epidemiology, risk factors, diagnosis, and management. Scand J Gastroenterol. 52:803–815. 2017. View Article : Google Scholar : PubMed/NCBI

Bernard V, Semaan A, Huang J, San Lucas FA, Mulu FC, Stephens BM, Guerrero PA, Huang Y, Zhao J, Kamyabi N, et al: Single-cell transcriptomics of pancreatic cancer precursors demonstrates epithelial and microenvironmental heterogeneity as an early event in neoplastic progression. Clin Cancer Res. 25:2194–2205. 2019. View Article : Google Scholar

Storandt MH, Zemla TM, Patell K, Naleid N, Gile JJ, Tran NH, Chakrabarti S, Jin Z, Borad M and Mahipal A: Atezolizumab plus bevacizumab as first-line systemic therapy for hepatocellular carcinoma: A multi-institutional cohort study. Oncologist. 29:986–996. 2024. View Article : Google Scholar : PubMed/NCBI

Selene II, Ozen M and Patel RA: Hepatocellular carcinoma: Advances in systemic therapy. Semin Intervent Radiol. 41:56–62. 2024. View Article : Google Scholar : PubMed/NCBI

Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, Jou JH, Kulik LM, Agopian VG, Marrero JA, et al: AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 78:1922–1965. 2023. View Article : Google Scholar : PubMed/NCBI

Loh JJ, Li TW, Zhou L, Wong TL, Liu X, Ma VWS, Lo CM, Man K, Lee TK, Ning W, et al: FSTL1 secreted by activated fibroblasts promotes hepatocellular carcinoma metastasis and stemness. Cancer Res. 81:5692–5705. 2021. View Article : Google Scholar : PubMed/NCBI

Liu J, Chen S, Wang W, Ning BF, Chen F, Shen W, Ding J, Chen W, Xie WF, Zhang X, et al: Cancer-associated fibroblasts promote hepatocellular carcinoma metastasis through chemokine-activated hedgehog and TGF-β pathways. Cancer Lett. 379:49–59. 2016. View Article : Google Scholar : PubMed/NCBI

Jia CC, Wang TT, Liu W, Fu BS, Hua X, Wang GY, Li TJ, Li X, Wu XY, Tai Y, et al: Cancer-associated fibroblasts from hepatocellular carcinoma promote malignant cell proliferation by HGF secretion. PLoS One. 8:e632432013. View Article : Google Scholar : PubMed/NCBI

Xiong S, Wang R, Chen Q, Luo J, Wang J, Zhao Z, Li Y, Wang Y, Wang X and Cheng B: Cancer-associated fibroblasts promote stem cell-like properties of hepatocellular carcinoma cells through IL-6/STAT3/Notch signaling. Am J Cancer Res. 8:302–316. 2018.PubMed/NCBI

Li Y, Wang R, Xiong S, Wang X, Zhao Z, Bai S, Wang Y, Zhao Y and Cheng B: Cancer-associated fibroblasts promote the stemness of CD24+ liver cells via paracrine signaling. J Mol Med (Berl). 97:243–255. 2019. View Article : Google Scholar

Zhu GQ, Tang Z, Huang R, Qu WF, Fang Y, Yang R, Tao CY, Gao J, Wu XL, Sun HX, et al: CD36+ cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factor. Cell Discov. 9:252023. View Article : Google Scholar :

Eun JW, Yoon JH, Ahn HR, Kim S, Kim YB, Lim SB, Park W, Kang TW, Baek GO, Yoon MG, et al: Cancer-associated fibroblast-derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib. Cancer Commun (Lond). 43:455–479. 2023. View Article : Google Scholar : PubMed/NCBI

Xia S, Pan Y, Liang Y, Xu J and Cai X: The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma. EBioMedicine. 51:1026102020. View Article : Google Scholar : PubMed/NCBI

Yu L, Liu Q, Huo J, Wei F and Guo W: Cancer-associated fibroblasts induce immunotherapy resistance in hepatocellular carcinoma animal model. Cell Mol Biol (Noisy-le-Grand). 66:36–40. 2020. View Article : Google Scholar : PubMed/NCBI

Lotfollahzadeh S, Recio-Boiles A and Cagir B: Colon cancer. StatPearls. Treasure Island (FL) with ineligible companies. Disclosure: Alejandro Recio-Boiles declares no relevant financial relationships with ineligible companies. Disclosure: Burt Cagir declares no relevant financial relationships with ineligible companies.2024.

Constantinou V and Constantinou C: Focusing on colorectal cancer in young adults (Review). Mol Clin Oncol. 20:82024. View Article : Google Scholar

Siegel RL, Wagle NS, Cercek A, Smith RA and Jemal A: Colorectal cancer statistics, 2023. CA Cancer J Clin. 73:233–254. 2023.PubMed/NCBI

Zeineddine FA, Zeineddine MA, Yousef A, Gu Y, Chowdhury S, Dasari A, Huey RW, Johnson B, Kee B, Lee MS, et al: Survival improvement for patients with metastatic colorectal cancer over twenty years. NPJ Precis Oncol. 7:162023. View Article : Google Scholar : PubMed/NCBI

Morris VK, Kennedy EB, Baxter NN, Benson AB III, Cercek A, Cho M, Ciombor KK, Cremolini C, Davis A, Deming DA, et al: Treatment of metastatic colorectal cancer: ASCO Guideline. J Clin Oncol. 41:678–700. 2023. View Article : Google Scholar

Deng L, Jiang N, Zeng J, Wang Y and Cui H: The versatile roles of Cancer-associated fibroblasts in colorectal cancer and therapeutic implications. Front Cell Dev Biol. 9:7332702021. View Article : Google Scholar : PubMed/NCBI

Wikberg ML, Edin S, Lundberg IV, Van Guelpen B, Dahlin AM, Rutegård J, Stenling R, Oberg A and Palmqvist R: High intratumoral expression of fibroblast activation protein (FAP) in colon cancer is associated with poorer patient prognosis. Tumour Biol. 34:1013–1020. 2013. View Article : Google Scholar : PubMed/NCBI

Hu JL, Wang W, Lan XL, Zeng ZC, Liang YS, Yan YR, Song FY, Wang FF, Zhu XH, Liao WJ, et al: CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer. Mol Cancer. 18:912019. View Article : Google Scholar : PubMed/NCBI

Aizawa T, Karasawa H, Funayama R, Shirota M, Suzuki T, Maeda S, Suzuki H, Yamamura A, Naitoh T, Nakayama K and Unno M: Cancer-associated fibroblasts secrete Wnt2 to promote cancer progression in colorectal cancer. Cancer Med. 8:6370–6382. 2019. View Article : Google Scholar : PubMed/NCBI

Siegel RL, Giaquinto AN and Jemal A: Cancer statistics, 2024. CA Cancer J Clin. 74:12–49. 2024.PubMed/NCBI

Gridelli C, Rossi A, Carbone DP, Guarize J, Karachaliou N, Mok T, Petrella F, Spaggiari L and Rosell R: Non-small-cell lung cancer. Nat Rev Dis Primers. 1:150092015. View Article : Google Scholar : PubMed/NCBI

Herbst RS, Morgensztern D and Boshoff C: The biology and management of Non-small cell lung cancer. Nature. 553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI

Kim SH, Choe C, Shin YS, Jeon MJ, Choi SJ, Lee J, Bae GY, Cha HJ and Kim J: Human lung cancer-associated fibroblasts enhance motility of Non-small cell lung cancer cells in co-culture. Anticancer Res. 33:2001–2009. 2013.PubMed/NCBI

An J, Enomoto A, Weng L, Kato T, Iwakoshi A, Ushida K, Maeda K, Ishida-Takagishi M, Ishii G, Ming S, et al: Significance of cancer-associated fibroblasts in the regulation of gene expression in the leading cells of invasive lung cancer. J Cancer Res Clin Oncol. 139:379–388. 2013. View Article : Google Scholar

Chen WJ, Ho CC, Chang YL, Chen HY, Lin CA, Ling TY, Yu SL, Yuan SS, Chen YJ, Lin CY, et al: Cancer-associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signalling. Nat Commun. 5:34722014. View Article : Google Scholar : PubMed/NCBI

Wang L, Cao L, Wang H, Liu B, Zhang Q, Meng Z, Wu X, Zhou Q and Xu K: Cancer-associated fibroblasts enhance metastatic potential of lung cancer cells through IL-6/STAT3 signaling pathway. Oncotarget. 8:76116–76128. 2017. View Article : Google Scholar : PubMed/NCBI

Vicent S, Sayles LC, Vaka D, Khatri P, Gevaert O, Chen R, Zheng Y, Gillespie AK, Clarke N, Xu Y, et al: Cross-species functional analysis of cancer-associated fibroblasts identifies a critical role for CLCF1 and IL-6 in non-small cell lung cancer in vivo. Cancer Res. 72:5744–5756. 2012. View Article : Google Scholar : PubMed/NCBI

Yang F, Yan Y, Yang Y, Hong X, Wang M, Yang Z, Liu B and Ye L: MiR-210 in exosomes derived from CAFs promotes non-small cell lung cancer migration and invasion through PTEN/PI3K/AKT pathway. Cell Signal. 73:1096752020. View Article : Google Scholar : PubMed/NCBI

Xiang H, Ramil CP, Hai J, Zhang C, Wang H, Watkins AA, Afshar R, Georgiev P, Sze MA, Song XS, et al: Cancer-associated fibroblasts promote immunosuppression by inducing ROS-generating monocytic MDSCs in lung squamous cell carcinoma. Cancer Immunol Res. 8:436–450. 2020. View Article : Google Scholar : PubMed/NCBI

Kanwal B, Biswas S, Seminara RS and Jeet C: Immunotherapy in advanced Non-small cell lung cancer patients: Ushering chemotherapy through the checkpoint inhibitors? Cureus. 10:e32542018.PubMed/NCBI

Herzog BH, Baer JM, Borcherding N, Kingston NL, Belle JI, Knolhoff BL, Hogg GD, Ahmad F, Kang LI, Petrone J, et al: Tumor-associated fibrosis impairs immune surveillance and response to immune checkpoint blockade in non-small cell lung cancer. Sci Transl Med. 15:eadh80052023. View Article : Google Scholar : PubMed/NCBI

Jenkins L, Jungwirth U, Avgustinova A, Iravani M, Mills A, Haider S, Harper J and Isacke CM: Cancer-associated fibroblasts suppress CD8+ T-cell infiltration and confer resistance to Immune-checkpoint blockade. Cancer Res. 82:2904–2917. 2022. View Article : Google Scholar : PubMed/NCBI

Tauriello DVF: Targeting CAFs to improve Anti-PD-1 checkpoint immunotherapy. Cancer Res. 83:655–656. 2023. View Article : Google Scholar : PubMed/NCBI

Shintani Y, Kimura T, Funaki S, Ose N, Kanou T and Fukui E: Therapeutic targeting of Cancer-associated fibroblasts in the Non-small cell lung cancer tumor microenvironment. Cancers (Basel). 15:3352023. View Article : Google Scholar : PubMed/NCBI

Li M, Wu B, Li L, Lv C and Tian Y: Reprogramming of cancer-associated fibroblasts combined with immune checkpoint inhibitors: A potential therapeutic strategy for cancers. Biochimica et biophysica acta. Rev Cancer. 1878:1889452023. View Article : Google Scholar

Rawla P: Epidemiology of prostate cancer. World J Oncol. 10:63–89. 2019. View Article : Google Scholar : PubMed/NCBI

Culp MB, Soerjomataram I, Efstathiou JA, Bray F and Jemal A: Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. 77:38–52. 2020. View Article : Google Scholar

Hammerer P and Manka L: Androgen deprivation therapy for advanced prostate cancer. Urologic Oncology. Merseburger AS and Burger M: Springer International Publishing; Cham: pp. 255–276. 2019, View Article : Google Scholar

Figueiredo A, Costa L, Mauricio MJ, Figueira L, Ramos R and Martins-da-Silva C: Nonmetastatic castration-resistant prostate cancer: Current challenges and trends. Clin Drug Investig. 42:631–642. 2022. View Article : Google Scholar : PubMed/NCBI

Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC and Mihatsch MJ: Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients. Hum Pathol. 31:578–583. 2000. View Article : Google Scholar : PubMed/NCBI

Begley LA, Kasina S, MacDonald J and Macoska JA: The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy. Cytokine. 43:194–199. 2008. View Article : Google Scholar : PubMed/NCBI

Levesque C and Nelson PS: Cellular constituents of the prostate stroma: Key contributors to prostate cancer progression and therapy resistance. Cold Spring Harb Perspect Med. 8:a0305102018. View Article : Google Scholar

ChallaSivaKanaka S, Vickman RE, Kakarla M, Hayward SW and Franco OE: Fibroblast heterogeneity in prostate carcinogenesis. Cancer Lett. 525:76–83. 2022. View Article : Google Scholar :

Franco OE and Hayward SW: Targeting the tumor stroma as a novel therapeutic approach for prostate cancer. Adv Pharmacol. 65:267–313. 2012. View Article : Google Scholar : PubMed/NCBI

Jung Y, Kim JK, Shiozawa Y, Wang J, Mishra A, Joseph J, Berry JE, McGee S, Lee E, Sun H, et al: Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. Nat Commun. 4:17952013. View Article : Google Scholar : PubMed/NCBI

Bavik C, Coleman I, Dean JP, Knudsen B, Plymate S and Nelson PS: The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res. 66:794–802. 2006. View Article : Google Scholar : PubMed/NCBI

Bedeschi M, Marino N, Cavassi E, Piccinini F and Tesei A: Cancer-associated fibroblast: Role in prostate cancer progression to metastatic disease and therapeutic resistance. Cells. 12:8022023. View Article : Google Scholar : PubMed/NCBI

Bonollo F, Thalmann GN, Kruithof-de Julio M and Karkampouna S: The role of Cancer-Associated fibroblasts in prostate cancer tumorigenesis. Cancers (Basel). 12:18872020. View Article : Google Scholar : PubMed/NCBI

Lavie D, Ben-Shmuel A, Erez N and Scherz-Shouval R: Cancer-associated fibroblasts in the single-cell era. Nat Cancer. 3:793–807. 2022. View Article : Google Scholar : PubMed/NCBI

Nguyen EV, Pereira BA, Lawrence MG, Ma X, Rebello RJ, Chan H, Niranjan B, Wu Y, Ellem S, Guan X, et al: Proteomic profiling of human prostate Cancer-associated fibroblasts (CAF) reveals LOXL2-dependent regulation of the tumor microenvironment. Mol Cell Proteomics. 18:1410–1427. 2019. View Article : Google Scholar : PubMed/NCBI

Wadosky KM and Koochekpour S: Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer. Oncotarget. 7:64447–64470. 2016. View Article : Google Scholar : PubMed/NCBI

Boudadi K and Antonarakis ES: Resistance to novel antiandrogen therapies in metastatic Castration-resistant prostate cancer. Clin Med Insights Oncol. 10(Suppl 1): S1–S9. 2016.

Chandrasekar T, Yang JC, Gao AC and Evans CP: Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol. 4:365–380. 2015.

Leach DA and Buchanan G: Stromal androgen receptor in prostate cancer development and progression. Cancers (Basel). 9:102017. View Article : Google Scholar : PubMed/NCBI

Cioni B, Nevedomskaya E, Melis MHM, van Burgsteden J, Stelloo S, Hodel E, Spinozzi D, de Jong J, van der Poel H, de Boer JP, et al: Loss of androgen receptor signaling in prostate cancer-associated fibroblasts (CAFs) promotes CCL2- and CXCL8-mediated cancer cell migration. Mol Oncol. 12:1308–1323. 2018. View Article : Google Scholar : PubMed/NCBI

Eder T, Weber A, Neuwirt H, Grünbacher G, Ploner C, Klocker H, Sampson N and Eder IE: Cancer-associated fibroblasts modify the response of prostate cancer cells to androgen and Anti-androgens in Three-dimensional spheroid culture. Int J Mol Sci. 17:14582016. View Article : Google Scholar : PubMed/NCBI

Cheteh EH, Augsten M, Rundqvist H, Bianchi J, Sarne V, Egevad L, Bykov VJ, Östman A and Wiman KG: Human cancer-associated fibroblasts enhance glutathione levels and antagonize drug-induced prostate cancer cell death. Cell Death Dis. 8:e28482017. View Article : Google Scholar : PubMed/NCBI

Baumhoer D, Hench J and Amary F: Recent advances in molecular profiling of bone and soft tissue tumors. Skeletal Radiol. 53:1925–1936. 2024. View Article : Google Scholar : PubMed/NCBI

Anderson WJ and Doyle LA: Updates from the 2020 World health organization classification of soft tissue and bone tumours. Histopathology. 78:644–657. 2021. View Article : Google Scholar : PubMed/NCBI

Ehnman M, Chaabane W, Haglund F and Tsagkozis P: The tumor microenvironment of pediatric sarcoma: Mesenchymal mechanisms regulating cell migration and metastasis. Curr Oncol Rep. 21:902019. View Article : Google Scholar : PubMed/NCBI

Plikus MV, Wang X, Sinha S, Forte E, Thompson SM, Herzog EL, Driskell RR, Rosenthal N, Biernaskie J and Fibroblasts Horsley V: Origins, definitions, and functions in health and disease. Cell. 184:3852–3872. 2021. View Article : Google Scholar : PubMed/NCBI

Resag A, Toffanin G, Benesova I, Müller L, Potkrajcic V, Ozaniak A, Lischke R, Bartunkova J, Rosato A, Jöhrens K, et al: The immune contexture of liposarcoma and its clinical implications. Cancers. 14:45782022. View Article : Google Scholar : PubMed/NCBI

Jones JEC, Rabhi N, Orofino J, Gamini R, Perissi V, Vernochet C and Farmer SR: The adipocyte acquires a fibroblast-like transcriptional signature in response to a high fat diet. Sci Rep. 10:23802020. View Article : Google Scholar : PubMed/NCBI

Lendahl U, Muhl L and Betsholtz C: Identification, discrimination and heterogeneity of fibroblasts. Nat Commun. 13:34092022. View Article : Google Scholar : PubMed/NCBI

Bochet L, Lehuede C, Dauvillier S, Wang YY, Dirat B, Laurent V, Dray C, Guiet R, Maridonneau-Parini I, Le Gonidec S, et al: Adipocyte-derived fibroblasts promote tumor progression and contribute to the desmoplastic reaction in breast cancer. Cancer Res. 73:5657–5668. 2013. View Article : Google Scholar : PubMed/NCBI

Bouche C and Quail DF: Fueling the tumor microenvironment with cancer-associated adipocytes. Cancer Res. 83:1170–1172. 2023. View Article : Google Scholar : PubMed/NCBI

Harati K, Daigeler A, Hirsch T, Jacobsen F, Behr B, Wallner C, Lehnhardt M and Becerikli M: Tumor-associated fibroblasts promote the proliferation and decrease the doxorubicin sensitivity of liposarcoma cells. Int J Mol Med. 37:1535–1541. 2016. View Article : Google Scholar : PubMed/NCBI

Xu C, Yan L, Guan X, Wang Z, Wu J, Lv A, Liu D, Liu F, Dong B, Zhao M, et al: Tsp2 facilitates tumor-associated fibroblasts formation and promotes tumor progression in retroperitoneal liposarcoma. Int J Biol Sci. 18:5038–5055. 2022. View Article : Google Scholar : PubMed/NCBI

Kalluri R: The biology and function of fibroblasts in cancer. Nat Rev Cancer. 16:582–598. 2016. View Article : Google Scholar : PubMed/NCBI

Skapek SX, Ferrari A, Gupta AA, Lupo PJ, Butler E, Shipley J, Barr FG and Hawkins DS: Rhabdomyosarcoma. Nat Rev Dis Primers. 5:12019. View Article : Google Scholar : PubMed/NCBI

Hettmer S and Wagers AJ: Muscling in: Uncovering the origins of rhabdomyosarcoma. Nat Med. 16:171–173. 2010. View Article : Google Scholar : PubMed/NCBI

Chapman MA, Meza R and Lieber RL: Skeletal muscle fibroblasts in health and disease. Differentiation. 92:108–115. 2016. View Article : Google Scholar : PubMed/NCBI

Tarnowski M, Grymula K, Liu R, Tarnowska J, Drukala J, Ratajczak J, Mitchell RA, Ratajczak MZ and Kucia M: Macrophage migration inhibitory factor is secreted by rhabdomyosarcoma cells, modulates tumor metastasis by binding to CXCR4 and CXCR7 receptors and inhibits recruitment of cancer-associated fibroblasts. Mol Cancer Res. 8:1328–1343. 2010. View Article : Google Scholar : PubMed/NCBI

Wysoczynski M, Shin DM, Kucia M and Ratajczak MZ: Selective upregulation of interleukin-8 by human rhabdomyosarcomas in response to hypoxia: Therapeutic implications. Int J Cancer. 126:371–381. 2010. View Article : Google Scholar

Awaji M, Saxena S, Wu L, Prajapati DR, Purohit A, Varney ML, Kumar S, Rachagani S, Ly QP, Jain M, et al: CXCR2 signaling promotes secretory cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. FASEB J. 34:9405–9418. 2020. View Article : Google Scholar : PubMed/NCBI

Dhayni K, Zibara K, Issa H, Kamel S and Bennis Y: Targeting CXCR1 and CXCR2 receptors in cardiovascular diseases. Pharmacol Ther. 237:1082572022. View Article : Google Scholar : PubMed/NCBI

Ghayad SE, Rammal G, Ghamloush F, Basma H, Nasr R, Diab-Assaf M, Chelala C and Saab R: Exosomes derived from embryonal and alveolar rhabdomyosarcoma carry differential miRNA cargo and promote invasion of recipient fibroblasts. Sci Rep. 6:370882016. View Article : Google Scholar : PubMed/NCBI

Fahs A, Hussein N, Zalzali H, Ramadan F, Ghamloush F, Tamim H, El Homsi M, Badran B, Boulos F, Tawil A, et al: CD147 promotes tumorigenesis via Exosome-mediated signaling in rhabdomyosarcoma. Cells. 11:22672022. View Article : Google Scholar : PubMed/NCBI

Burns J, Wilding CP, Krasny L, Zhu X, Chadha M, Tam YB, Ps H, Mahalingam AH, Lee ATJ, Arthur A, et al: The proteomic landscape of soft tissue sarcomas. Nature Commun. 14:38342023. View Article : Google Scholar

Stork T, Hegedus B, Guder W, Hamacher R, Hardes J, Kaths M, Plönes T, Pöttgen C, Schildhaus HU, Streitbürger A, et al: Prognostic factors for leiomyosarcoma with isolated metastases to the lungs: Impact of metastasectomy. Ann Surg Oncol. 29:4429–4436. 2022. View Article : Google Scholar : PubMed/NCBI

Tseng WW, Swallow CJ, Strauss DC, Bonvalot S, Rutkowski P, Ford SJ, Gonzalez RJ, Gladdy RA, Gyorki DE, Fairweather M, et al: Management of locally recurrent retroperitoneal sarcoma in the Adult: An updated consensus approach from the transatlantic australasian retroperitoneal sarcoma working group. Ann Surg Oncol. 29:7335–7348. 2022. View Article : Google Scholar : PubMed/NCBI

Tran V and Slavin J: Immunohistochemistry in bone and soft tissue tumours. Sarcoma: A Practical Guide to Multidisciplinary Management. Choong PFM: Springer Singapore; Singapore: pp. 119–134. 2021, View Article : Google Scholar

Porrello G, Cannella R, Randazzo A, Badalamenti G, Brancatelli G and Vernuccio F: CT and MR imaging of retroperitoneal sarcomas: A practical guide for the radiologist. Cancers (Basel). 15:29852023. View Article : Google Scholar : PubMed/NCBI

Kerrison WGJ, Thway K, Jones RL and Huang PH: The biology and treatment of leiomyosarcomas. Crit Rev Oncol Hematol. 184:1039552023. View Article : Google Scholar : PubMed/NCBI

Tai Y, Woods EL, Dally J, Kong D, Steadman R, Moseley R and Midgley AC: Myofibroblasts: Function, formation, and scope of molecular therapies for skin fibrosis. Biomolecules. 11:10952021. View Article : Google Scholar : PubMed/NCBI

Nagao Y, Yokoi A, Yoshida K, Kitagawa M, Asano-Inami E, Kato T, Ishikawa M, Yamamoto Y and Kajiyama H: Uterine leiomyosarcoma cell-derived extracellular vesicles induce the formation of cancer-associated fibroblasts. Biochim Biophys Acta Mol Basis Dis. 1870:1671032024. View Article : Google Scholar : PubMed/NCBI

Canter RJ, Beal S, Borys D, Martinez SR, Bold RJ and Robbins AS: Interaction of histologic subtype and histologic grade in predicting survival for soft-tissue sarcomas. J Am Coll Surg. 210:191–198.e2. 2010. View Article : Google Scholar : PubMed/NCBI

Sun H, Liu J, Hu F, Xu M, Leng A, Jiang F and Chen K: Current research and management of undifferentiated pleomorphic sarcoma/myofibrosarcoma. Front Genet. 14:11094912023. View Article : Google Scholar : PubMed/NCBI

Ozzello L, Stout AP and Murray MR: Cultural characteristics of malignant histiocytomas and fibrous xanthomas. Cancer. 16:331–344. 1963. View Article : Google Scholar : PubMed/NCBI

O'Brien JE and Stout AP: Malignant fibrous xanthomas. Cancer. 17:1445–1455. 1964. View Article : Google Scholar : PubMed/NCBI

Iwasaki H, Isayama T, Johzaki H and Kikuchi M: Malignant fibrous histiocytoma. Evidence of perivascular mesenchymal cell origin immunocytochemical studies with monoclonal anti-MFH antibodies. Am J Pathol. 128:528–537. 1987.PubMed/NCBI

Erlandson RA and Antonescu CR: The rise and fall of malignant fibrous histiocytoma. Ultrastruct Pathol. 28:283–289. 2004. View Article : Google Scholar

Widemann BC and Italiano A: Biology and management of undifferentiated pleomorphic sarcoma, myxofibrosarcoma, and malignant peripheral nerve sheath tumors: State of the art and perspectives. J Clin Oncol. 36:160–167. 2018. View Article : Google Scholar :

Osanai T, Yamakawa M, Suda A and Watanabe Y: Metamorphosed fibroblasts and their relation to the histogenesis of malignant fibrous histiocytoma in experimental murine model. Histol Histopathol. 15:697–705. 2000.PubMed/NCBI

Taxy JB and Battifora H: Malignant fibrous histiocytoma. An electron microscopic study. Cancer. 40:254–267. 1977. View Article : Google Scholar : PubMed/NCBI

Wood GS, Beckstead JH, Turner RR, Hendrickson MR, Kempson RL and Warnke RA: Malignant fibrous histiocytoma tumor cells resemble fibroblasts. Am J Surg Pathol. 10:323–335. 1986. View Article : Google Scholar : PubMed/NCBI

Chang Y, Cho B, Kim S and Kim J: Direct conversion of fibroblasts to osteoblasts as a novel strategy for bone regeneration in elderly individuals. Exp Mol Med. 51:1–8. 2019.PubMed/NCBI

Neumann E, Lefevre S, Zimmermann B, Gay S and Muller-Ladner U: Rheumatoid arthritis progression mediated by activated synovial fibroblasts. Trends Mol Med. 16:458–468. 2010. View Article : Google Scholar : PubMed/NCBI

Setty BA, Gikandi A and DuBois SG: Ewing sarcoma drug therapy: Current standard of care and emerging agents. Paediatr Drugs. 25:389–397. 2023. View Article : Google Scholar : PubMed/NCBI

Riggi N, Suva ML and Stamenkovic I: Ewing's Sarcoma. N Engl J Med. 384:154–164. 2021. View Article : Google Scholar : PubMed/NCBI

Volchenboum SL, Andrade J, Huang L, Barkauskas DA, Krailo M, Womer RB, Ranft A, Potratz J, Dirksen U, Triche TJ and Lawlor ER: Gene expression profiling of ewing sarcoma tumors reveals the prognostic importance of Tumor-stromal interactions: A report from the Children's oncology group. J Pathol Clin Res. 1:83–94. 2015. View Article : Google Scholar : PubMed/NCBI

Wrenn ED, Apfelbaum AA, Rudzinski ER, Deng X, Jiang W, Sud S, Van Noord RA, Newman EA, Garcia NM, Miyaki A, et al: Cancer-associated Fibroblast-like tumor cells remodel the ewing sarcoma tumor microenvironment. Clin Cancer Res. 29:5140–5154. 2023. View Article : Google Scholar : PubMed/NCBI

Li S, Zhang H, Liu J and Shang G: Targeted therapy for osteosarcoma: A review. J Cancer Res Clin Oncol. 149:6785–6797. 2023. View Article : Google Scholar : PubMed/NCBI

Panez-Toro I, Munoz-Garcia J, Vargas-Franco JW, Renodon-Cornière A, Heymann MF, Lézot F and Heymann D: Advances in osteosarcoma. Curr Osteoporos Rep. 21:330–343. 2023. View Article : Google Scholar : PubMed/NCBI

Misaghi A, Goldin A, Awad M and Kulidjian AA: Osteosarcoma: A comprehensive review. SICOT J. 4:122018. View Article : Google Scholar : PubMed/NCBI

Hu J, Lazar AJ, Ingram D, Wang WL, Zhang W, Jia Z, Ragoonanan D, Wang J, Xia X, Mahadeo K, et al: Cell membrane-anchored and tumor-targeted IL-12 T-cell therapy destroys cancer-associated fibroblasts and disrupts extracellular matrix in heterogenous osteosarcoma xenograft models. J Immunother Cancer. 12:e0069912024. View Article : Google Scholar : PubMed/NCBI

Wang JW, Wu XF, Gu XJ and Jiang XH: Exosomal miR-1228 from Cancer-associated fibroblasts promotes cell migration and invasion of osteosarcoma by directly targeting SCAI. Oncol Res. 27:979–986. 2019. View Article : Google Scholar

Mazumdar A, Urdinez J, Boro A, Migliavacca J, Arlt MJE, Muff R, Fuchs B, Snedeker JG and Gvozdenovic A: Osteosarcoma-derived extracellular vesicles induce lung fibroblast reprogramming. Int J Mol Sci. 21:54512020. View Article : Google Scholar : PubMed/NCBI

Zhang Y, Liu Z, Yang X, Lu W, Chen Y, Lin Y, Wang J, Lin S and Yun JP: H3K27 acetylation activated-COL6A1 promotes osteosarcoma lung metastasis by repressing STAT1 and activating pulmonary cancer-associated fibroblasts. Theranostics. 11:1473–1492. 2021. View Article : Google Scholar : PubMed/NCBI

David MS, Kelly E and Zoellner H: Opposite cytokine synthesis by fibroblasts in contact co-culture with osteosarcoma cells compared with transwell co-cultures. Cytokine. 62:48–51. 2013. View Article : Google Scholar : PubMed/NCBI

Xu Y, Chen P, Liu D, Xu Q, Meng H and Wang X: Exploration of s new biomarker in osteosarcoma and association with clinical outcomes: TOP2A+ cancer associated fibroblasts. J Gene Med. 25:e35282023. View Article : Google Scholar

Liu Y, Han X, Han Y, Bi J, Wu Y, Xiang D, Zhang Y, Bi W, Xu M and Li J: Integrated transcriptomic analysis systematically reveals the heterogeneity and molecular characterization of cancer-associated fibroblasts in osteosarcoma. Gene. 907:1482862024. View Article : Google Scholar : PubMed/NCBI

LeBleu VS and Neilson EG: Origin and functional heterogeneity of fibroblasts. FASEB. 34:3519–3536. 2020. View Article : Google Scholar

Pittenger MF, Discher DE, Peault BM, Phinney DG, Hare JM and Caplan AI: Mesenchymal stem cell perspective: Cell biology to clinical progress. NPJ Regen Med. 4:222019. View Article : Google Scholar : PubMed/NCBI

Sannino G, Marchetto A, Kirchner T and Grunewald TGP: Epithelial-to-mesenchymal and mesenchymal-to-epithelial transition in mesenchymal tumors: A paradox in sarcomas? Cancer Res. 77:4556–4561. 2017. View Article : Google Scholar : PubMed/NCBI

Mehta A and Stanger BZ: Lineage Plasticity: The new cancer hallmark on the block. Cancer Res. 84:184–191. 2024. View Article : Google Scholar :

Strating E, Verhagen MP, Wensink E, Dünnebach E, Wijler L, Aranguren I, De la Cruz AS, Peters NA, Hageman JH, van der Net MMC, et al: Co-cultures of colon cancer cells and cancer-associated fibroblasts recapitulate the aggressive features of mesenchymal-like colon cancer. Front Immunol. 14:10539202023. View Article : Google Scholar : PubMed/NCBI

Jeong SY, Lee JH, Shin Y, Chung S and Kuh HJ: Co-culture of tumor spheroids and fibroblasts in a collagen Matrix-incorporated microfluidic chip mimics reciprocal activation in solid tumor microenvironment. PLoS One. 11:e01590132016. View Article : Google Scholar : PubMed/NCBI

Abercrombie M, Heaysman JE and Karthauser HM: Social behaviour of cells in tissue culture. III. Mutual influence of sarcoma cells and fibroblasts. Exp Cell Res. 13:276–291. 1957. View Article : Google Scholar : PubMed/NCBI

Abercrombie M and Heaysman JE: Invasive behavior between sarcoma and fibroblast populations in cell culture. J Natl Cancer Inst. 56:561–570. 1976. View Article : Google Scholar : PubMed/NCBI

Johnson GS, Friedman RM and Pastan I: Restoration of several morphological characteristics of normal fibroblasts in sarcoma cells treated with adenosine-3': 5'-cyclic monophosphate and its derivatives. Proc Natl Acad Sci USA. 68:425–429. 1971. View Article : Google Scholar

Dahlberg WK, Little JB, Fletcher JA, Suit HD and Okunieff P: Radiosensitivity in vitro of human soft tissue sarcoma cell lines and skin fibroblasts derived from the same patients. Int J Radiat Biol. 63:191–198. 1993. View Article : Google Scholar : PubMed/NCBI

Fisher C: Low-grade sarcomas with CD34-positive fibroblasts and Low-grade myofibroblastic sarcomas. Ultrastruct Pathol. 28:291–305. 2004. View Article : Google Scholar

Broz MT, Ko EY, Ishaya K, Xiao J, De Simone M, Hoi XP, Piras R, Gala B, Tessaro FHG, Karlstaedt A, et al: Metabolic targeting of cancer associated fibroblasts overcomes T-cell exclusion and chemoresistance in Soft-tissue sarcomas. Nat Commun. 15:24982024. View Article : Google Scholar : PubMed/NCBI

Liu Y, Sinjab A, Min J, Han G, Paradiso F, Zhang Y, Wang R, Pei G, Dai Y, Liu Y, et al: Conserved spatial subtypes and cellular neighborhoods of cancer-associated fibroblasts revealed by single-cell spatial multi-omics. Cancer Cell. 43:905–924.e6. 2025. View Article : Google Scholar : PubMed/NCBI

Kazakova AN, Lukina MM, Anufrieva KS, Bekbaeva IV, Ivanova OM, Shnaider PV, Slonov A, Arapidi GP and Shender VO: Exploring the diversity of cancer-associated fibroblasts: Insights into mechanisms of drug resistance. Front Cell Dev Biol. 12:14031222024. View Article : Google Scholar : PubMed/NCBI

Chen Y, McAndrews KM and Kalluri R: Clinical and therapeutic relevance of cancer-associated fibroblasts. Nat Rev Clin Oncol. 18:792–804. 2021. View Article : Google Scholar : PubMed/NCBI

Wang LC, Lo A, Scholler J, Sun J, Majumdar RS, Kapoor V, Antzis M, Cotner CE, Johnson LA, Durham AC, et al: Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol Res. 2:154–166. 2014. View Article : Google Scholar : PubMed/NCBI

Liu Y, Sun Y, Wang P, Li S, Dong Y, Zhou M, Shi B, Jiang H, Sun R and Li Z: FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer. J Transl Med. 21:2552023. View Article : Google Scholar : PubMed/NCBI

Gao Y, Li X, Zeng C, Liu C, Hao Q, Li W, Zhang K, Zhang W, Wang S, Zhao H, et al: CD63+ Cancer-associated fibroblasts confer tamoxifen resistance to breast cancer cells through exosomal miR-22. Adv Sci (Weinh). 7:20025182020. View Article : Google Scholar

Zhou P, Du X, Jia W, Feng K and Zhang Y: Engineered extracellular vesicles for targeted reprogramming of cancer-associated fibroblasts to potentiate therapy of pancreatic cancer. Signal Transduct Target Ther. 9:1512024. View Article : Google Scholar : PubMed/NCBI

Peng D, Fu M, Wang M, Wei Y and Wei X: Targeting TGF-β signal transduction for fibrosis and cancer therapy. Mol Cancer. 21:1042022. View Article : Google Scholar

Akhmetshina A, Palumbo K, Dees C, Bergmann C, Venalis P, Zerr P, Horn A, Kireva T, Beyer C, Zwerina J, et al: Activation of canonical Wnt signalling is required for TGF-beta-mediated fibrosis. Nat Commun. 3:7352012. View Article : Google Scholar

Xu L, Cui WH, Zhou WC, Li DL, Li LC, Zhao P, Mo XT, Zhang Z and Gao J: Activation of Wnt/β-catenin signalling is required for TGF-β/Smad2/3 signalling during myofibroblast proliferation. J Cell Mol Med. 21:1545–1554. 2017. View Article : Google Scholar : PubMed/NCBI

Giguelay A, Turtoi E, Khelaf L, Tosato G, Dadi I, Chastel T, Poul MA, Pratlong M, Nicolescu S, Severac D, et al: The landscape of cancer-associated fibroblasts in colorectal cancer liver metastases. Theranostics. 12:7624–7639. 2022. View Article : Google Scholar : PubMed/NCBI

Li H, Liu W, Zhang X and Wang Y: Cancer-associated fibroblast-secreted collagen triple helix repeat containing-1 promotes breast cancer cell migration, invasiveness and epithelial-mesenchymal transition by activating the Wnt/β-catenin pathway. Oncol Lett. 22:8142021.

Avgustinova A, Iravani M, Robertson D, Fearns A, Gao Q, Klingbeil P, Hanby AM, Speirs V, Sahai E, Calvo F and Isacke CM: Tumour cell-derived Wnt7a recruits and activates fibroblasts to promote tumour aggressiveness. Nat Commun. 7:103052016. View Article : Google Scholar : PubMed/NCBI

Sun Y, Campisi J, Higano C, Beer TM, Porter P, Coleman I, True L and Nelson PS: Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med. 18:1359–1368. 2012. View Article : Google Scholar : PubMed/NCBI

Kramer N, Schmollerl J, Unger C, Nivarthi H, Rudisch A, Unterleuthner D, Scherzer M, Riedl A, Artaker M, Crncec I, et al: Autocrine WNT2 signaling in fibroblasts promotes colorectal cancer progression. Oncogene. 36:5460–5472. 2017. View Article : Google Scholar : PubMed/NCBI

Zhang C, Fei Y, Wang H, Hu S, Liu C, Hu R and Du Q: CAFs orchestrates tumor immune microenvironment-A new target in cancer therapy? Front Pharmacol. 14:11133782023. View Article : Google Scholar : PubMed/NCBI

Huang TX, Tan XY, Huang HS, Li YT, Liu BL, Liu KS, Chen X, Chen Z, Guan XY, Zou C and Fu L: Targeting cancer-associated fibroblast-secreted WNT2 restores dendritic cell-mediated antitumour immunity. Gut. 71:333–344. 2022. View Article : Google Scholar

Moynihan KD, Kumar MP, Sultan H, Pappas DC, Park T, Chin SM, Bessette P, Lan RY, Nguyen HC, Mathewson ND, et al: IL-2 targeted to CD8+ T cells promotes robust effector T cell responses and potent antitumor immunity. Cancer Discov. 14:1206–1225. 2024. View Article : Google Scholar : PubMed/NCBI

Siebert N, Leopold J, Zumpe M, Troschke-Meurer S, Biskupski S, Zikoridse A and Lode HN: The immunocytokine FAP-IL-2v enhances anti-neuroblastoma efficacy of the anti-GD2 antibody dinutuximab beta. Cancers. 14:48422022. View Article : Google Scholar :

Rivas EI, Linares J, Zwick M, Gómez-Llonin A, Guiu M, Labernadie A, Badia-Ramentol J, Lladó A, Bardia L, Pérez-Núñez I, et al: Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+ breast tumors. Nat Commun. 13:53102022. View Article : Google Scholar : PubMed/NCBI

Karthik R, Deshpande NU, Iago de Castro S, Anna B, Ifeanyichukwu O, Haleh A, Andrews A, Vanessa G, Siddharth M, Samara S, et al: Abstract C021: Granulocytic MDSC-derived NLRP3 inflammasome activation is a novel regulator of inflammatory CAF skewness in pancreatic cancer. In: Proceedings of the AACR Special Conference in Cancer Research: Pancreatic Cancer; 2023 Sep 27-30; Boston, Massachusetts. Philadelphia (PA), AACR. Cancer Res. 84(Suppl 2)2024.Abstract nr C021.

Shao X, Zhao X, Wang B, Fan J, Wang J and An H: Tumor microenvironment targeted nano-drug delivery systems for multidrug resistant tumor therapy. Theranostics. 15:1689–1714. 2025. View Article : Google Scholar : PubMed/NCBI

Crane JN, Graham DS, Mona CE, Nelson SD, Samiei A, Dawson DW, Dry SM, Masri MG, Crompton JG, Benz MR, et al: Fibroblast activation protein expression in sarcomas. Sarcoma. 2023:24804932023. View Article : Google Scholar : PubMed/NCBI

Miettinen M: Immunohistochemistry of soft tissue tumours-review with emphasis on 10 markers. Histopathology. 64:101–118. 2014. View Article : Google Scholar

Zhang H, Yue X, Chen Z, Liu C, Wu W, Zhang N, Liu Z, Yang L, Jiang Q, Cheng Q, et al: Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: New opportunities in cancer immunotherapy and advances in clinical trials. Mol Cancer. 22:1592023. View Article : Google Scholar : PubMed/NCBI

Brahmi M, Lesluyes T, Dufresne A, Toulmonde M, Italiano A, Mir O, Le Cesne A, Valentin T, Chevreau C, Bonvalot S, et al: Expression and prognostic significance of PDGF ligands and receptors across soft tissue sarcomas. ESMO Open. 6:1000372021. View Article : Google Scholar : PubMed/NCBI

Robin YM, Penel N, Perot G, Neuville A, Vélasco V, Ranchère-Vince D, Terrier P and Coindre JM: Transgelin is a novel marker of smooth muscle differentiation that improves diagnostic accuracy of leiomyosarcomas: A comparative immunohistochemical reappraisal of myogenic markers in 900 soft tissue tumors. Mod Pathol. 26:502–510. 2013. View Article : Google Scholar

Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G, Rahman A, Chen G, Staten A, Griebel D and Pazdur R: Approval summary: Imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res. 8:3034–3038. 2002.PubMed/NCBI

Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, Agulnik M, Cooney MM, Livingston MB, Pennock G, et al: Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: An open-label phase 1b and randomised phase 2 trial. Lancet. 388:488–497. 2016. View Article : Google Scholar : PubMed/NCBI

Tap WD, Wagner AJ, Schoffski P, Martin-Broto J, Krarup-Hansen A, Ganjoo KN, Yen CC, Abdul Razak AR, Spira A, Kawai A, et al: Effect of doxorubicin plus olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas: The ANNOUNCE randomized clinical trial. JAMA. 323:1266–1276. 2020. View Article : Google Scholar : PubMed/NCBI

Martin-Broto J, Hindi N, Grignani G, Martinez-Trufero J, Redondo A, Valverde C, Stacchiotti S, Lopez-Pousa A, D'Ambrosio L, Gutierrez A, et al: Nivolumab and sunitinib combination in advanced soft tissue sarcomas: A multicenter, Single-arm, phase Ib/II trial. J Immunother Cancer. 8:e0015612020. View Article : Google Scholar : PubMed/NCBI

Shahvali S, Rahiman N, Jaafari MR and Arabi L: Targeting fibroblast activation protein (FAP): Advances in CAR-T cell, antibody, and vaccine in cancer immunotherapy. Drug Deliv Transl Res. 13:2041–2056. 2023. View Article : Google Scholar : PubMed/NCBI

Xiao W, Wang J, Wen X, Xu B, Que Y, Yu K, Xu L, Zhao J, Pan Q, Zhou P and Zhang X: Chimeric antigen receptor-modified T-cell therapy for platelet-derived growth factor receptor α-positive rhabdomyosarcoma. Cancer. 126(Suppl 9): S2093–S2100. 2020. View Article : Google Scholar

Vogt KC, Silberman PC, Lin Q, Han JE, Laflin A, Gellineau HA, Heller DA and Scheinberg DA: Microenvironment actuated CAR T cells improve solid tumor efficacy without toxicity. Sci Adv. 11:eads34032025. View Article : Google Scholar : PubMed/NCBI

Dharani S, Cho H, Fernandez JP, Juillerat A, Valton J, Duchateau P, Poirot L and Das S: TALEN-edited allogeneic inducible dual CAR T cells enable effective targeting of solid tumors while mitigating off-tumor toxicity. Mol Ther. 32:3915–3931. 2024. View Article : Google Scholar : PubMed/NCBI

Liu H, Yang W and Jiang J: Targeting tumor metabolism to augment CD8+ T cell anti-tumor immunity. J Pharm Anal. 15:1011502025. View Article : Google Scholar :

Ben-Ami E, Perret R, Huang Y, Courgeon F, Gokhale PC, Laroche-Clary A, Eschle BK, Velasco V, Le Loarer F, Algeo MP, et al: LRRC15 targeting in Soft-tissue sarcomas: Biological and clinical implications. Cancers (Basel). 12:572020. View Article : Google Scholar

Slemmons KK, Mukherjee S, Meltzer P, Purcell JW and Helman LJ: LRRC15 antibody-drug conjugates show promise as osteosarcoma therapeutics in preclinical studies. Pediatr Blood Cancer. 68:e287712021. View Article : Google Scholar

Brennen WN, Isaacs JT and Denmeade SR: Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol Cancer Ther. 11:257–266. 2012. View Article : Google Scholar : PubMed/NCBI

Giammarile F, Knoll P, Paez D, Estrada Lobato E, Calapaqui Teran AK and Delgado Bolton RC: Fibroblast activation protein inhibitor (FAPI) PET imaging in sarcomas: A new frontier in nuclear medicine. Semin Nucl Med. 54:340–344. 2024. View Article : Google Scholar : PubMed/NCBI

Greifenstein L, Gunkel A, Hoehne A, Osterkamp F, Smerling C, Landvogt C, Mueller C and Baum RP: 3BP-3940, a highly potent FAP-targeting peptide for theranostics-production, validation and first in human experience with Ga-68 and Lu-177. iScience. 26:1085412023. View Article : Google Scholar

Xie N, Shen G, Gao W, Huang Z, Huang C and Fu L: Neoantigens: Promising targets for cancer therapy. Signal Transduct Target Ther. 8:92023. View Article : Google Scholar : PubMed/NCBI

Kirane A, Lee D and Ariyan C: Surgical considerations in Tumor-infiltrating lymphocyte therapy: Challenges and opportunities. Transplant Cell Ther. 31(Suppl 1): S591–S598. 2025. View Article : Google Scholar : PubMed/NCBI

Fan S, Wang W, Che W, Xu Y, Jin C, Dong L and Xia Q: Nanomedicines targeting metabolic pathways in the tumor microenvironment: Future perspectives and the role of AI. Metabolites. 15:2012025. View Article : Google Scholar : PubMed/NCBI

Di Dedda C, Vignali D, Piemonti L and Monti P: Pharmacological targeting of GLUT1 to control Autoreactive T cell responses. Int J Mol Sci. 20:49622019. View Article : Google Scholar : PubMed/NCBI

Macintyre AN, Gerriets VA, Nichols AG, Michalek RD, Rudolph MC, Deoliveira D, Anderson SM, Abel ED, Chen BJ, Hale LP and Rathmell JC: The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. Cell Metab. 20:61–72. 2014. View Article : Google Scholar : PubMed/NCBI

Sung KE, Su X, Berthier E, Pehlke C, Friedl A and Beebe DJ: Understanding the impact of 2D and 3D fibroblast cultures on in vitro breast cancer models. PLoS One. 8:e763732013. View Article : Google Scholar : PubMed/NCBI

Tolle RC, Gaggioli C and Dengjel J: Three-dimensional cell culture conditions affect the proteome of cancer-associated fibroblasts. J Proteome Res. 17:2780–2789. 2018. View Article : Google Scholar : PubMed/NCBI

Shao H, Moller M, Wang D, Ting A, Boulina M and Liu ZJ: A Novel stromal Fibroblast-modulated 3D tumor spheroid model for studying Tumor-stroma interaction and drug discovery. J Vis Exp. Feb 28–2020. View Article : Google Scholar

Chen H, Cheng Y, Wang X, Wang J, Shi X, Li X, Tan W and Tan Z: 3D printed in vitro tumor tissue model of colorectal cancer. Theranostics. 10:12127–12143. 2020. View Article : Google Scholar : PubMed/NCBI

Mondal A, Gebeyehu A, Miranda M, Bahadur D, Patel N, Ramakrishnan S, Rishi AK and Singh M: Characterization and printability of Sodium alginate-Gelatin hydrogel for bioprinting NSCLC co-culture. Sci Rep. 9:199142019. View Article : Google Scholar

Kuen J, Darowski D, Kluge T and Majety M: Pancreatic cancer cell/fibroblast co-culture induces M2 like macrophages that influence therapeutic response in a 3D model. PLoS One. 12:e01820392017. View Article : Google Scholar : PubMed/NCBI

Jobe NP, Rosel D, Dvořánková B, Kodet O, Lacina L, Mateu R, Smetana K and Brábek J: Simultaneous blocking of IL-6 and IL-8 is sufficient to fully inhibit CAF-induced human melanoma cell invasiveness. Histochem Cell Biol. 146:205–217. 2016. View Article : Google Scholar : PubMed/NCBI

Balachander GM, Talukdar PM, Debnath M, Rangarajan A and Chatterjee K: Inflammatory role of Cancer-associated fibroblasts in invasive breast tumors revealed using a fibrous polymer scaffold. ACS Appl Mater Interfaces. 10:33814–33826. 2018. View Article : Google Scholar : PubMed/NCBI

Linxweiler J, Hajili T, Körbel C, Berchem C, Zeuschner P, Müller A, Stöckle M, Menger MD, Junker K and Saar M: Cancer-associated fibroblasts stimulate primary tumor growth and metastatic spread in an orthotopic prostate cancer xenograft model. Sci Reps. 10:125752020. View Article : Google Scholar

Miyazaki Y, Oda T, Inagaki Y, Kushige H, Saito Y, Mori N, Takayama Y, Kumagai Y, Mitsuyama T and Kida YS: Adipose-derived mesenchymal stem cells differentiate into heterogeneous cancer-associated fibroblasts in a stroma-rich xenograft model. Sci Rep. 11:46902021. View Article : Google Scholar : PubMed/NCBI

Wahbi W, Awad S, Salo T and Al-Samadi A: Stroma modulation of radiation response in head and neck squamous cell carcinoma: Insights from zebrafish larvae xenografts. Exp Cell Res. 435:1139112024. View Article : Google Scholar : PubMed/NCBI

Foster DS, Januszyk M, Delitto D, Yost KE, Griffin M, Guo J, Guardino N, Delitto AE, Chinta M, Burcham AR, et al: Multiomic analysis reveals conservation of cancer-associated fibroblast phenotypes across species and tissue of origin. Cancer Cell. 40:1392–1406.e7. 2022. View Article : Google Scholar : PubMed/NCBI

Cho C, Mukherjee R, Peck AR, Sun Y, McBrearty N, Katlinski KV, Gui J, Govindaraju PK, Puré E, Rui H and Fuchs SY: Cancer-associated fibroblasts downregulate type I interferon receptor to stimulate intratumoral stromagenesis. Oncogene. 39:6129–6137. 2020. View Article : Google Scholar : PubMed/NCBI

Helms EJ, Berry MW, Chaw RC, DuFort CC, Sun D, Onate MK, Oon C, Bhattacharyya S, Sanford-Crane H, Horton W, et al: Mesenchymal lineage heterogeneity underlies nonredundant functions of pancreatic Cancer-associated fibroblasts. Cancer Discov. 12:484–501. 2022. View Article : Google Scholar

De Vita A, Recine F, Miserocchi G, Pieri F, Spadazzi C, Cocchi C, Vanni S, Liverani C, Farnedi A, Fabbri F, et al: The potential role of the extracellular matrix in the activity of trabectedin in UPS and L-sarcoma: Evidences from a patient-derived primary culture case series in tridimensional and zebrafish models. J Exp Clin Cancer Res. 40:1652021. View Article : Google Scholar : PubMed/NCBI

Molina ER, Chim LK, Salazar MC, Koons GL, Menegaz BA, Ruiz-Velasco A, Lamhamedi-Cherradi SE, Vetter AM, Satish T, Cuglievan B, et al: 3D Tissue-engineered tumor model for Ewing's sarcoma that incorporates Bone-like ECM and mineralization. ACS Biomater Sci Eng. 6:539–552. 2020. View Article : Google Scholar

Moghimi N, Hosseini SA, Dalan AB, Mohammadrezaei D, Goldman A and Kohandel M: Controlled tumor heterogeneity in a co-culture system by 3D bio-printed tumor-on-chip model. Sci Rep. 13:136482023. View Article : Google Scholar : PubMed/NCBI

Yang D, Jones MG, Naranjo S, Rideout WM III, Min KHJ, Ho R, Wu W, Replogle JM, Page JL, Quinn JJ, et al: Lineage tracing reveals the phylodynamics, plasticity, and paths of tumor evolution. Cell. 185:1905–1923.e25. 2022. View Article : Google Scholar : PubMed/NCBI

Simeonov KP, Byrns CN, Clark ML, Norgard RJ, Martin B, Stanger BZ, Shendure J, McKenna A and Lengner CJ: Single-cell lineage tracing of metastatic cancer reveals selection of hybrid EMT states. Cancer Cell. 39:1150–1162.e9. 2021. View Article : Google Scholar : PubMed/NCBI

Liu J, Liu C, Ma Y, Pan X, Chu R, Yao S, Chen J, Liu C, Chen Z, Sheng C, et al: STING inhibitors sensitize platinum chemotherapy in ovarian cancer by inhibiting the CGAS-STING pathway in cancer-associated fibroblasts (CAFs). Cancer Lett. 588:2167002024. View Article : Google Scholar : PubMed/NCBI

de Kruijf EM, van Nes JG, van de Velde CJ, Putter H, Smit VT, Liefers GJ, Kuppen PJ, Tollenaar RA and Mesker WE: Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients. Breast Cancer Res Treat. 125:687–696. 2011. View Article : Google Scholar

Huijbers A, Tollenaar RA, v Pelt GW, Zeestraten EC, Dutton S, McConkey CC, Domingo E, Smit VT, Midgley R, Warren BF, et al: The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: Validation in the VICTOR trial. Ann Oncol. 24:179–185. 2013. View Article : Google Scholar

De Vlieghere E, Verset L, Demetter P, Bracke M and De Wever O: Cancer-associated fibroblasts as target and tool in cancer therapeutics and diagnostics. Virchows Arch. 467:367–382. 2015. View Article : Google Scholar : PubMed/NCBI

Kanzaki R and Pietras K: Heterogeneity of cancer-associated fibroblasts: Opportunities for precision medicine. Cancer Sci. 111:2708–2717. 2020. View Article : Google Scholar : PubMed/NCBI

Wang Q, Zhang X, Du K, Wu X, Zhou Y, Chen D and Zeng L: Machine learning identifies characteristics molecules of cancer associated fibroblasts significantly correlated with the prognosis, immunotherapy response and immune microenvironment in lung adenocarcinoma. Front Oncol. 12:10592532022. View Article : Google Scholar : PubMed/NCBI

Shen C, Rawal S, Brown R, Zhou H, Agarwal A, Watson MA, Cote RJ and Yang C: Automatic detection of circulating tumor cells and cancer associated fibroblasts using deep learning. Sci Rep. 13:57082023. View Article : Google Scholar : PubMed/NCBI

Agnoletto C, Caruso C and Garofalo C: Heterogeneous circulating tumor cells in sarcoma: Implication for clinical practice. Cancers (Basel). 13:21892021. View Article : Google Scholar : PubMed/NCBI

Yang Z, Zhou D and Huang J: Identifying explainable machine learning models and a novel SFRP2+ fibroblast signature as predictors for precision medicine in ovarian cancer. Int J Mol Sci. 24:169422023. View Article : Google Scholar :

Min KW, Kim DH, Noh YK, Son BK, Kwon MJ and Moon JY: Cancer-associated fibroblasts are associated with poor prognosis in solid type of lung adenocarcinoma in a machine learning analysis. Sci Rep. 11:167792021. View Article : Google Scholar : PubMed/NCBI

Huang B, Chen Q, Ye Z, Zeng L, Huang C, Xie Y, Zhang R and Shen H: Construction of a matrix Cancer-associated fibroblast signature Gene-based risk prognostic signature for directing immunotherapy in patients with breast cancer using Single-cell analysis and machine learning. Int J Mol Sci. 24:131752023. View Article : Google Scholar : PubMed/NCBI

Ao Z, Shah SH, Machlin LM, Parajuli R, Miller PC, Rawal S, Williams AJ, Cote RJ, Lippman ME, Datar RH and El-Ashry D: Identification of Cancer-associated fibroblasts in circulating blood from patients with metastatic breast cancer. Cancer Res. 75:4681–4687. 2015. View Article : Google Scholar : PubMed/NCBI

Booijink R, Terstappen LWMM, Dathathri E, Isebia K, Kraan J, Martens J and Bansal R: Identification of functional and diverse circulating cancer-associated fibroblasts in metastatic Castration-naive prostate cancer patients. Mol Oncol. 19:2074–2091. 2024. View Article : Google Scholar

Lu T, Oomens L, Terstappen L and Prakash J: In vivo detection of circulating cancer-associated fibroblasts in breast tumor mouse xenograft: Impact of tumor stroma and chemotherapy. Cancers (Basel). 15:11272023. View Article : Google Scholar : PubMed/NCBI